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Abstract 
 
Bringing together topic-related European Union-(EU)-funded projects, the so-called “NanoSafety Cluster” aims at 
identifying key areas for further research on risk assessment procedures for nanomaterials (NM). The outcome of 
NanoSafety Cluster Working Group 10, this commentary presents a vision for concern-driven integrated 
approaches for the (eco-)toxicological testing and assessment (IATA) of NM. Such approaches should start out 
by determining concerns, i.e. specific information needs for a given NM based on realistic exposure scenarios. 
Recognized concerns can be addressed in a set of tiers using standardized protocols for NM preparation and 
testing. Tier 1 includes determining physico-chemical properties, non-testing (e.g. structure activity relationships) 
and evaluating existing data. In tier 2, a limited set of in vitro and in vivo tests are performed that can either 
indicate that the risk of the specific concern is sufficiently known or indicate the need for further testing, including 
details for such testing. Ecotoxicological testing begins with representative test organisms followed by complex 
test systems. After each tier, it is evaluated whether the information gained permits assessing the safety of the 
NM so that further testing can be waived. By effectively exploiting all available information, IATA allow 
accelerating the risk assessment process and reducing testing costs and animal use (in line with the 3Rs 
principle implemented in EU Directive 2010/63/EU). Combining material properties, exposure, biokinetics, and 
hazard data, information gained with IATA can be used to recognize groups of NM based upon similar modes-of-
action. Grouping of substances in return should form integral part of the IATA themselves. 
Background 
 
Recognizing nanotechnology as an enabling technology contributing to innovation, economic 
growth, employment, and competitiveness, the European Union’s (EU) Commission, in its 
second regulatory review on nanomaterials, has reinforced its continuous commitment to 
promoting research and development in this area (Anon., 2012a). Warranting the safety of 
nanotechnological products is seen as a crucial element in ensuring that the benefits of the 
new technology can be fully exploited. Therefore, up until the end of 2012, the Commission 
has funded a total of 46 nanosafety projects representing a total EU investment of 130 
Million EUR (Anon., 2012b). To facilitate the formation of consensus on nanotoxicology, the 
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Commission has requested EU-funded nanosafety projects to join forces through the so-
called NanoSafety Cluster (Anon., 2012b). The members of this initiative have assigned 
themselves the goal to identify key areas of nanosafety research which are likely to be of 
special significance in the coming years (NanoSafety Cluster, 2011). Covering all aspects of 
nanomaterial characterization, exposure and hazard assessment, research challenges 
relating to these key areas are further specified in topic-specific Working Groups. In 
delineating a timeframe for meeting such challenges, the NanoSafety Cluster has taken on 
the deadline of 2020, a year that has been spelled out by the Commission both in the 
Europe 2020 strategy for smart, sustainable and inclusive growth (Anon., 2010a) and for the 
upcoming Research Framework Programme Horizon 2020 (Anon., 2011a).  
 
The present commentary summarizes the outcome of the discussions of NanoSafety Cluster 
Working Group (WG) 10 on integrated approaches to testing and assessment (IATA) of 
nanomaterials (NM). Such approaches, in the literature also referred to as integrated testing 
strategies, are required for an adequate assessment of the impact of NM on human health 
and the environment. Whereas WG 10 has pursued its deliberations on IATA independently 
of existing regulations, they do stand in line with current EU guidance on NM safety testing. 
In the context of REACH Regulation 1907/2006 (Registration, Evaluation, Authorisation of 
Chemicals; Anon., 2006), a testing strategy for NM should consider the procedure 
established for conventional chemicals expanded to address the specific peculiarities of NM 
(RIP-oN 2, 2011).  
 
One prominent trait of NM is the fact that, during the life-time of a given NM, humans and the 
environment can be exposed to different forms of the material, e.g. due to agglomeration or 
aggregation, corona formation or interaction with surrounding organic material, or 
dissolution. Hence, it is of paramount importance for adequate testing to ensure that the 
testing conditions applied (including NM characteristics and exposure conditions) are 
appropriate to assess the risk under relevant real-life exposure situations. One aspect is that 
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the physico-chemical properties of the nanomaterial during testing are known, either by 
analytical techniques or standardized techniques when suspending or dispersing NM for 
toxicity testing. One way or another, this issue needs to be addressed in the risk assessment 
strategy for NM. 
 
Since a multitude of different NM in different exposure scenarios is expected, it will not be 
possible to perform all-embracing testing of all NM in all relevant scenarios. Instead, testing 
must be targeted to the actual concerns for a given NM making use of realistic exposure 
scenarios. Moreover, a testing strategy should include possibilities for the grouping of NM 
(e.g. by applying a ‘read-across’ methodology, some tests could be waived based on a 
categorization of NM), and should also aid the grouping concept itself (e.g. the testing 
strategy should provide information that is relevant for grouping).  
 
The actual concerns associated with a given NM should be determined in relation to material 
properties, specific exposure situations, biokinetic data, and/or markers of early biological 
effects. They should be used to define the crucial human health and environmental 
endpoints to be tested in focused studies, including the test designs of these studies. All of 
these issues should be considered for the grouping of NM which, in return, should form 
integral part of the IATA. The integrated NM toxicity and ecotoxicity testing approaches 
proposed in this commentary are based on these considerations. 
State-of-the-art 
 
Multiple toxicity studies with NM have been carried out in the last decade. However, most of 
them used non-standardized testing protocols leading to sometimes not reproducible and 
hardly comparable results, which therefore are insufficient for univocal hazard and risk 
assessment. In addition, the unavailability of consistent physico-chemical characterization 
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data in the same studies makes it difficult to identify which (combinations of) material 
characteristics determine the documented toxic effects. One reason behind the lack of 
convincing patterns could be that characterization has been performed ex situ, since NM are 
generally difficult to characterize in situ (Tiede et al., 2008, Card and Magnuson, 2010). 
Nevertheless, it has been shown that a variety of factors such as ionic strength, pH and 
other media-specific properties cause changes to the primary NM once they enter media 
(e.g. related to NM agglomeration, aggregation, and surface modification), which affects both 
their bioavailability and toxicity (Hassellov et al., 2008). Besides, the results are derived 
using a variety of dispersion and analytical protocols and here again standard methods 
require to be developed. 
 
Current toxicological approaches to assess hazards of NM are either based on methods 
adopted from classical toxicology or on alternative methods. These approaches do not fully 
consider the unique aspects of NM, e.g. (1) different forms of a given NM in different 
biological media; (2) uptake/absorption, distribution, corona formation and 
elimination/deposition (ADCE, used by analogy to ADME, absorption, distribution, 
metabolism, excretion; since, for most NM, metabolism, unlike corona formation, does not 
play a major role.); (3) functional impacts at the organ and cellular levels.  
 
Slow elimination and persistence are main drivers for bioaccumulation. Similar to 
conventional hydrophobic persistent chemicals, such as DDT, that are resistant to 
environmental and biological degradation, NM have the potential to accumulate in humans 
and biota (food chain) when exposure takes place on, e.g., a daily basis. Presently, the 
structure and dynamics of protein corona are considered to be key to the nanoparticle’s rate 
of uptake and transport into cells and final subcellular localization (Nel et al., 2009; Lundqvist 
et al., 2011). A number of proteomics methods to identify the nature, composition, and 
dynamics of the biomolecules associated to NM have been developed (Lai et al., 2012). 
Without suitable information on the potential for NM to bioaccumulate, it is not possible to 
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carry out higher-tier human health or environmental risk assessment or to derive 
Environmental Quality Standards (Anon., 2008).   
 
While the risk assessment of conventional substances is based on the notion that their 
chemical identity governs the biological effects of a substance, there is general agreement 
that the toxicity of NM is determined by a set of characteristics, e.g. size, shape, surface 
area, charge. Given the substantial diversity within each group of nanomaterials and the 
complexity of nanosystems (e.g. stability of dispersions under different conditions), a large 
number of property combinations need to be considered in order to assess the overall 
hazard of a single material type. Currently, it is widely accepted among scientists and 
regulators that the hazard/risk assessment of NM can only be addressed on a case-by-case 
basis. However, considering the large number of existing and emerging nanoformulations, 
this would be a time and resource intensive task, conflicting with the 3Rs principle to replace, 
reduce, and refine animal testing (Russell and Burch, 1959) implemented in EU Directive 
2010/63/EU on the protection of animals used for scientific purposes (Anon., 2010b). In this 
context, IATA have become particularly relevant since they are intended to speed up the risk 
assessment process, while at the same time reducing testing costs and animal use by 
effectively exploiting all existing data (van Leeuwen et al., 2007; Hartung, 2009). Integrated 
processes consolidate all available information (including both exposure and toxicity 
information) to identify relevant concerns and to determine the information that best 
addresses these concerns (focusing on toxicity studies and/or exposure information). 
  
The need for standardization and new approaches in the nanosafety area has been 
recognized. In parallel to ongoing scientific research, a number of international initiatives 
have been launched, such as the OECD Working Party on Manufactured Nanomaterials 
(OECD WPMN; see: http://www.oecd.org/env/ehs/nanosafety/ note: all websites were 
accessed in February and March 2013) and the ISO Technical Committee 229 (see: 
http://www.iso.org/iso/iso_technical_committee?commid=381983).  
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Of particular importance for the above discussions are the OECD WPMN Steering Groups 
(SG) 6 and 7. SG 6 deals with risk assessment approaches, such as ‘read-across’ 
methodologies, and SG 7 addresses the use of alternative test methods and integrated 
testing strategies for NM hazard assessment. This Steering Group has proposed a new 
short-term inhalation study (STIS) for NM testing (OECD, 2011) and has compiled a list of in 
vitro methods that might be used for NM human hazard identification. Furthermore, it has 
initiated a similar discussion for environmental impacts. Comparable structures of the human 
and environmental hazard identification frameworks aim at allowing a better integration of 
human health and ecological risk assessment into one coherent strategy and at facilitating 
its implementation for regulatory purposes. 
Vision beyond the state-of-the-art  
 
The NanoSafety Cluster vision 2020 foresees the development of a concern-driven guidance 
for investigating potential risks of NM. This will enable focused research on NM that may be 
of particular concern based on (expected) exposure levels and exposure routes, material 
properties as well as in silico, hazard and biokinetic data. By advocating that animals are 
only used for crucial and focused studies minimizing numbers of animals used and the 
distress inflicted upon the animals, this approach further meets the provisions of EU 
Directive 2010/63/EU (Anon., 2010b). 
 
Based upon these considerations, IATA will be developed allowing for different sequences of 
testing depending in the types of NM. Such IATA will start out by identifying relevant 
concerns, based on NM exposure and use scenarios and taking into account already 
available toxicological information and basic information assessed by non-testing (structure 
activity relationships (SAR), generic physiologically-based pharmacokinetic (PBPK) 
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modeling based on in vitro data, and grouping), proceeding with tests using acellular 
systems and then cellular systems, up until in vivo, long-term testing approaches, if deemed 
necessary (Johnston et al., 2013). These strategies will be based on a thorough 
understanding of the biokinetics of a given NM in exposure-relevant media and matrixes 
(e.g. medium-dependent agglomeration, dispersion, etc.) enabled by a continuous sampling, 
analysis, and characterization paradigm. They will be designed both for human health and 
environmental safety/risk assessment, e.g. by mimicking realistic exposure scenarios and by 
using appropriate dose levels for different purposes and in different situations. Finally, these 
strategies will be based on validated methods with established predictive power.  
 
Such guidance, to be fully developed and effective by 2020 and beyond, will require less 
testing whenever the available information is sufficient and adequate for decision-making. 
For instance, if an NM rapidly dissolves, the substance should be treated as a conventional 
chemical, although the assessment of dissolution, and under which conditions and in which 
media, could be the actual, underlying challenge (remaining to be addressed in future 
research projects, such as NanoREG; see: 
http://ihcp.jrc.ec.europa.eu/our_activities/nanotechnology/symp2012/doc/van_Teunenbroek_
Research_Reg_needs_s2.pdf). At the same time it will be possible to obtain more 
information from the selected tests, e.g. on the particles’ mechanism of action (Rossini and 
Hartung, 2012; Nel et al., 2013). Nevertheless, the guidance might also imply requiring more 
information if it is necessary to address specific concerns (e.g. immunotoxicity, 
cardiovascular toxicity, neurotoxicity, developmental toxicity). Eventually, it will be inevitable 
to discuss which level of certainty on the potential risks of a given NM in a specific 
application should be required. 
 
Furthermore, by 2020 and beyond, guidance will be developed and effective on when NM 
(based on physico-chemical characteristics, exposure, and early biological effects) can be 
grouped, how these groupings should be constructed, and what kind of information is 
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necessary to be able to group. In addition to avoiding extensive hazard testing of NM, this 
will also provide insight on the conditions under which information on exposure and hazard 
for NM can be used for risk assessment purposes (Som et al., 2012).  
 
This vision 2020 of the NanoSafety Cluster should be realized in the context of existing 
international and national chemical regulatory frameworks taking into account existing OECD 
Test Guidelines (TG) and adapted as appropriate to take into account the specific properties 
of NM, as recommended by the OECD Chemicals Committee (OECD, 2013). Following on a 
mid-term evaluation of the OECD’s nanosafety programme in 2012, the Chemicals 
Committee, a parent body to the WPMN, additionally recommended updating existing OECD 
TG or including new ones in the light of experience with NM, to apply the OECD principles of 
Good Laboratory Practice to NM safety testing, and to make safety data related to NM 
available to the public (OECD, 2013). 
 
NM dispersion and in situ characterization for toxicity testing 
 
On the one hand, meaningful exposures allowing to understand and monitor the important 
characteristics of real-life exposure and to correctly interpret the test results cannot be 
mimicked in all toxicological test systems (Hristozov et al., 2013). On the other hand, the 
form of the NM (agglomeration state, corona, etc.) can be largely dependent on the 
exposure scenario. Therefore, test sample preparation by dispersion of the respective NM is 
a critical step for toxicity testing, and it must be well considered and appropriate (Rothen-
Rutishauser et al., 2010). Likewise, the resulting test sample dispersions (both stock and test 
solutions) have to be characterized. Over the past years, multiple dispersion protocols have 
been used and an extensive list of parameters for in situ characterization has been proposed 
(Schulze et al., 2008; Card and Magnuson, 2009; SCENIHR, 2009; OECD, 2010). Figure 1 
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lists characterization parameters currently considered relevant for NM preparation and safety 
testing. 
Testing strategies to assess NM biopersistence and biokinetics 
 
NM may potentially cross portals of entry into the body, such as the gills, the gastrointestinal 
tract, lung epithelium, or skin, and also internal barriers, such as the blood-brain barrier, 
placenta, and blood-testis barrier. NM with different characteristics (size, coating, shape) 
may differ considerably in the extent of their transportation across these barriers. The types 
of particles that can be transferred across barriers have not been systematically 
investigated, and to date very little is known about the parameters that influence differences 
in the extent of transportation (Oberdörster, 2009; Landsiedel et al., 2012). However, such 
information will be relevant to determine if NM have reached the systemic circulation, and if 
so, to what extent bioavailability is increased, and whether, for instance, systemic effects, 
including cardiovascular or immunological toxicity, should be considered. 
 
In contrast to many soluble chemicals, NM generally tend to disappear rapidly from the blood 
by being taken up into tissues, mainly those containing phagocytic cells. The apparent very 
short blood-plasma half-life stands in sharp contrast with the apparent long whole-body or 
tissue half-life. Once filtered from the blood by macrophages, NM tend to stay in these cells 
and in similar cell types, and they undergo whole-body elimination only to a fairly limited 
extent. Strong indications for this are already available for a number of NM, such as silver, 
SiO2, and cerium nanoparticles (Lankveld et al., 2010; Dan et al., 2012). 
 
Coatings as intentional modifications of the NM surface impact the effect on organisms by 
e.g. increasing the blood-plasma half-life (such as in the case of polyethylene glycol-(PEG)-
coated NM). Likewise, unintentional surface modifications may have an impact on the tissue 
distribution of NM, as well as on the rate in which distribution occurs (Liu et al., 2012). A 
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“protein corona” is likely to be formed around the NM when they enter the body or even 
already before, e.g. when they are added to food products (Nel et al., 2009; Lundqvist et al., 
2011; Johnston et al., 2012). It should be noted that the corona of biological molecules 
covering the NM surface is most likely composed not only of proteins, but also of lipids and 
carbohydrates (Gasser et al., 2010). This “bio-corona” surrounding NM is dynamic, since the 
types of molecules forming it may change in time. Additionally, proteins and other molecules 
in the body fluids (mucus, blood, etc.) can differ significantly depending on the individual’s 
health conditions, thereby affecting the composition of the corona (Nel et al., 2009; Johnston 
et al., 2012). Similar to surface modifications of the NM, the corona affects the distribution 
pattern and the rate of distribution. This also implies that the uptake into cells is driven by the 
corona (Nel et al., 2009; Landsiedel et al., 2010). Concerning ecotoxicity, NM coating with 
organic molecules, such as humic acids or with minerals, is of relevance. More evidence is 
becoming available in regard to such issues, but this is still far too little to obtain a clear 
overview on the influence of NM surface modification and corona on bioavailability, 
biokinetics and cell entry. 
 
Effects of NM may be related to 1) the particles themselves and their coatings (particle 
effects); 2) ions or molecules released from the particles (chemical effects); and 3) 
molecules formed by the catalytic surface of the particle (nanorelated effects) (Landsiedel et 
al., 2010; Nel et al., 2013). In vitro dissolution tests in physiologically relevant media (e.g. 
lysosomal fluid, gastrointestinal fluid, lung lining fluid) may give indications on the time frame 
in which mainly particles, both particles and ions, and mainly ions are present (Dekkers et 
al., 2011 and 2012; EFSA, 2011). If particles are unlikely to dissolve, efforts should focus on 
long-term particle related effects, since the particles are likely to accumulate over time and 
exert their particle effects accordingly (Dekkers et al., 2012). If particles dissolve, both 
particle and ion-related toxicity should be considered. In that case, accumulation of particles 
is to be expected to a smaller extent, due to elimination by dissolution of particles to ions. 
The ion-related effects may be different from the effects of the dispersed particles. If NM 
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distribution and cellular uptake occurs in the particulate form, the ions may be released at 
different sites than when the NM are distributed as dispersed particles. Hence, the resulting 
toxicity may be different. 
 
Uptake by cells without significant clearance from those cells, as known for some NM, may 
pose a potential risk that up to now has not sufficiently been taken into account in the 
context of risk assessment. In order to prevent problems from arising, such as those 
encountered for persistent organic pollutants, information on long-term effects of NM should 
be addressed.  
 
In conclusion, the biokinetics of NM is certainly a research area of high priority. By 2020, the 
understanding of the mechanisms and significance of NM absorption via different routes, 
including de-agglomeration, and their distribution and translocation throughout the body, as 
well as cell type-specific NM uptake, breakdown and excretion will have markedly improved. 
Furthermore, the significance of biological barriers will be better understood and can be 
estimated based on simple tools (in silico, in vitro), allowing for a high throughput and 
reliable assessment of the possible risks posed by NM to human health and environmental 
species. Kinetic data and kinetic modeling should become tools to evaluate whether a 
specific NM behaves differently from another NM or from the corresponding bulk material. 
This should also allow assessment of whether NM can be grouped for risk assessment 
purposes. Based on such mechanistic understanding, it may also become possible to predict 
under which circumstances overload of various cell types is likely to occur.  
Testing strategies to assess NM human health hazards (i.e. toxicity) 
 
To date, no new type of toxic effect has been described for NM (i.e. no effects which have 
not been observed with any other substance or particle before). However, as has been 
discussed above, the uptake, tissue distribution, and clearance of NM may be different from 
Formatted: English (U.S.)
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dissolved molecules or larger particles. Nevertheless, the toxicity of NM can generally be 
tested by standard testing methods used for conventional chemicals, adapted to take into 
account, e.g. the NM-specific requirements for test sample preparation and characterization 
as well as test interference controls. Further adaptations of standard test methods may be 
necessary. It should be noted that these adaptations might not only be relevant for NM 
testing, but that they might be challenges for the modernization of safety testing approaches 
as such. 
 
Traditional toxicity testing is largely restricted to the mere observation of apical effects (i.e. 
clinical or histopathological manifestation of effects) and was performed according to an 
extensive list rather than a targeted strategy. A targeted testing strategy would be an 
efficient approach in line with the 3Rs principle: Fewer animals might be needed for testing, 
or more – and more relevant - information would become available with the reduced 
numbers of animals used (Silbergeld et al., 2011). A modern and efficient approach would 
address specific concerns for the respective NM in its given area of use (Nel et al., 2013).  
 
A concern-driven NM toxicity testing scheme consisting of three main tiers is presented in 
Figure 2. Tier 1 includes a concern assessment based on the physico-chemical 
characteristics of the specific NM and relevant scenarios for potential exposure, depending 
on its envisaged use. Such relevant exposure scenarios should take into account realistic 
dose levels that e.g. workers or consumers might be exposed to and whether nanomaterial 
exposure is likely to be in the aggregated or agglomerated states. For NM of concern 
identified in Tier 1, Tier 2 focuses on identifying their basic toxicological concerns, while Tier 
3 provides options to study specific endpoints of concern in more detail. The need for the 
performance of specific tests in the last tier is determined by the combined results of the first 
two tiers (Zuin et al., 2011; Cockburn et al., 2012). 
 
Formatted: Font: Italic
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Tiers 2 and 3 each consist of three parts, the so-called toxicity domain, the decision-making 
process, and the description of options for testing within each domain. Each toxicity domain 
reflects a specific toxicity endpoint or type of testing (e.g. repeated dose, biokinetics) to be 
addressed and contains a number of options for testing or non-testing, e.g. 
grouping/waiving) that can be selected in the decision-making process based upon the 
concerns identified in the preceding tier(s). 
 
In the following, these three tiers of the concern-driven toxicity testing strategy for NM are 
discussed in further detail: 
 
Tier 1. Identification of NM of concern (Figures 2 and 3) 
The first step of Tier 1 is the identification of the NM. This will depend on the definition of NM 
used (Bleeker et al., 2013). In the European Union, the respective Commission 
Recommendation (Anon., 2011b) defines a 'nanomaterial' to be a “natural, incidental or 
manufactured material containing particles, in an unbound state or as an aggregate or as an 
agglomerate and where, for 50 % or more of the particles in the number size distribution, 
one or more external dimensions is in the size range 1 nm - 100 nm”. The Commission 
recommendation provides for flexibility in the number size distribution threshold of 50% and 
lays down that “fullerenes, graphene flakes, and single wall carbon nanotubes with one or 
more external dimensions below 1 nm should [also] be considered as nanomaterials”.  
 
Many NM will not raise specific concerns, but will readily dissolve or form other, larger, 
particles (e.g. granular, biopersistent NM with low surface area and reactivity). However, 
other NM are likely to possess properties raising concerns for toxic effects (Figure 3, Step 2, 
identification of NM of potential concern). These concerns may be general or linked to 
specific uses and exposures (Figure 3, Step 3, identification of actual, relevant concerns). 
For instance, NM solely used in non-spray cosmetic sunscreen lotions may be of low 
Formatted: Font: Italic
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concern for inhalation toxicity for consumers. The output of Tier 1 might be a prioritization list 
for the testing of an individual NM in Tier 2. 
 
Tier 2. Basic testing (Figure 2) 
Concerns identified for an NM in its handling and use scenario can be addressed by 
(modified) standard test methods in a targeted strategy. At present, four toxicity domains are 
defined in Tier 2, i.e. biokinetics, local effects at the point of entry or primary contact, 
genotoxicity, and short-term toxicity (including inflammation and necrosis/cytotoxicity). Within 
each domain, a number of options for testing will be available, from which a selection for 
further testing can be made taking into account the concerns identified in Tier 1. For 
instance, the most relevant route of exposure or a potential for persistence identified in Tier 
1 will determine choices for testing, including test designs (e.g. parameters to be addressed, 
appropriate routes of exposure). Similarly, the order of testing can be decided upon to 
ensure that tests are combined meaningfully leading to best possible test designs and test 
results. During this decision-making phase, all available information will be considered. 
Grouping of substances (see also below) is seen as an integral part of the decision-making 
process: Based on grouping, it can be decided to waive specific tests or to confirm the 
necessity of a further test. The outcome of grouping can either be negative (no concern) or 
positive (a concern is confirmed based on the grouping). The latter will not automatically lead 
to further testing, but may lead to a decision, such as to stop research and development of 
the given substance or to the recommendation and application of adequate risk 
management measures. 
 
Tier 3. Specific testing (Figure 3) 
The outcome of Tier 2 tests will allow identification of the need for additional information and 
determining appropriate toxicity domain(s) to be addressed in Tier 3. The selection and 
design of tests for Tier 3 will thus be based on the information obtained during Tiers 1 and 2.  
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Considerations for decision criteria and testing options  
The options and decision criteria for testing within each toxicity domain of the presented 
testing strategy remain to be determined. Possible options for testing in Tiers 2 and 3, as 
illustrated in Figure 2, require completion. Of paramount importance, such criteria should 
ensure an overarching testing strategy and an integrated combination of tests rather than a 
set of separate tests for individual domains. The set of decision criteria should aim at 
obtaining the best possible data set, making use of the minimum number of tests possible. 
However, the criteria should not only relate to the identification of testing requirements, but 
also include options for waiving specific tests and provide guidance for grouping. If the need 
for specific additional tests is identified in the decision step of a given tier or is considered 
obligatory for grouping purposes, this will be described and included. An example for this 
may be a test for confirmation of a comparable mode-of-action.  
 
For several concerns, the expected toxic effect will be obvious from the composition (or 
shape or modification) of the NM and may thus be related to the bulk material (e.g. NM 
releasing zinc ions will show zinc toxicity). Differences in toxicity profiles may, however, arise 
from different distributions of a given NM. Once more, these considerations underline the 
importance of biokinetics and material properties (such as surface effects and persistence of 
NM in different biological media) in the context of NM toxicity testing (Krug and Wick, 2011). 
Therefore, the biokinetics (ADCE) of NM are to be specifically addressed in any NM testing 
strategy.  
 
Information on potential routes of exposure combined with indications for absorption across 
portals of entry determines the relevant route(s) of exposure to be chosen for testing 
systemic toxicity. Transportation across further barriers (placenta, blood-brain, blood-testis) 
will provide indications for the choice of (endpoint-)specific testing (such as testing for 
reproduction toxicity or neurotoxicity). During physico-chemical characterization, solubility in 
physiologically relevant media should be addressed to determine potential concern for long-
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lasting particle-related effects. If an NM, for which oral exposure is a relevant exposure 
route, dissolves in the gastrointestinal tract, only particle-related local effects on the 
gastrointestinal are anticipated (Dekkers et al., 2011; EFSA, 2011; Peters et al., 2012). If an 
NM dissolves within a couple of days in the macrophage/lysosome environment, equilibrium 
between intake and degradation will be reached within weeks, even upon daily exposure. 
Therefore, long-term particle related effects are unlikely. The potential use of information on 
dissolution for the risk assessment strategy should be investigated in more detail. Indications 
for biopersistence (in contrast to dissolution) and accumulation (to be investigated by a 
short-term kinetic study) of NM point to the need for long-term testing.  
 
So far, carcinogenic properties of NM in the lung have not been studied extensively (Becker 
et al., 2011), and very limited data on long-term studies by inhalation are available 
(Aschberger et al., 2011). Long-term inhalation studies with selected NM are required, also 
allowing recognizing pathways by which NM can cause lung tumors (e.g. inflammation, 
overload, genotoxicity). As soon as such general principles will be understood, less 
demanding tests can be applied in the toxicity testing strategies (e.g. short-term inhalation 
tests, genotoxicity, and cell transformation tests). The same concept of test selection could 
be used to address further possible concerns, such as detrimental cardiovascular effects. 
These considerations clearly indicate priorities for further research in nanosafety. 
 
Proposals for future testing strategies   
The testing strategy presented in Figure 2 is largely based on modified OECD standard 
methods extended with selected new methods, which partly were specifically developed for 
NM, such as short-term nanotoxicity studies (Ma-Hock et al., 2009; Klein et al., 2012). 
Further development of toxicological methods and increasing knowledge on NM adverse 
effects, their mechanism of action and the relevance of test results for the situation in 
humans will also alter the choice of test methods and improve NM toxicity testing strategies.  
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Toxicity testing of NM should make use of realistic models that represent different exposure 
scenarios. Silbergeld et al. (2011) discuss a potential modern testing battery for NM 
consisting of four elements. In recognition that rodent models oftentimes do not reproduce 
the reactivity found in humans, emphasis should be placed on in vitro models of human 
primary cells in tissue-like organization (Silbergeld et al., 2011). These may include barrier 
models (microvasculature endothelial cells, colon vs. small intestine, upper respiratory tract 
vs. alveolar space, skin) and models of the blood (in the case of intravenous delivery of 
nanomedicines).  
 
Complex models reproducing tissue architecture and conditions would provide scenarios 
much closer to the human situation than when using continuous transformed cell lines in 
vitro or animals in vivo. An example for such a complex model is colon tissue composed of 
primary enterocytes with M cells cultured on a thin porous support, with underlying lamina 
propria macrophages and dendritic cells, overlaid with mucus and enterobacteria (see e.g. 
Leonhard et al., 2012). Determination of NM effects in such models will allow a more 
comprehensive analysis of NM kinetics of interaction with the various extra-epithelial 
components of the biological system (mucus, bacteria, soluble factors), features of uptake by 
different mucosal cell types, intracellular trafficking, translocation between cells or 
compartments, and also biological effects, such as cell viability/damage (stress/autophagy, 
apoptosis, necrosis) and inflammatory cell activation (induction of inflammatory cytokines, 
inflammasome activation, down-regulation of inflammation inhibitors). In addition, such 
models can be adapted to reproducing conditions of disease (e.g. chronic gut inflammation, 
increased permeability, leukocyte influx, enhanced tissue destruction, impaired barrier 
function). This will allow testing different NM exposure scenarios, including those that are 
likely to be more relevant to safety assessment, e.g. in pathological or frailty conditions. 
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In the following, taking the example of genotoxicity testing, the choice of test methods, 
prevailing research needs, and the potential to improve existing methodologies shall be 
discussed.  
 
Based upon a comprehensive literature review, Landsiedel et al. (2009) have spelled out the 
following seven recommendations for genotoxicity testing of NM:  
1. Know the NM to be tested and its form; 
2. Recognize that NM are not all the same; 
3. Consider uptake and distribution of the NM; 
4. Take the NM-specific properties into account; 
5. Use standardized methods; 
6. Use in vivo studies and assess correlations with in vitro results; 
7. Use this information to compile the likely mechanisms of genotoxic effects. 
 
For many NM, both direct and indirect primary genotoxic effects as well as secondary ones 
can be partially explained as the result of enhanced production of oxidative stress which in 
return can lead to the induction of oxidative DNA damage (Bhattacharya et al., 2012; Kühnel 
et al., 2012). Thus, one of the main endpoints to be included in a range of assays addressing 
genotoxicity is oxidative DNA damage (Fenech, 2007). However no specific assay for 
oxidative damage detection is available as OECD Test Guideline, and the already widely 
used Comet assay remains under evaluation (Burlinson, 2012). 
 
Data obtained with general toxicity tests are of fundamental importance for studying 
genotoxic properties, since a comparison of genotoxicity to general toxicity is critical for any 
assessment of genotoxic effects. Efforts should be made to identify assays that can yield 
multiple results by analyzing many different endpoints simultaneously, such as both 
cytotoxicity and genotoxicity, and that can be applied to many cell types.  
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Recently, there has been growing interest in epigenetic changes in gene expression. Several 
epigenetic mechanisms, including DNA methylation, histone modifications, and microRNA 
expression, can change genome function under exogenous influence (Koturbash et al., 
2012). Many metals possibly act by epigenetic mechanisms. Therefore, nanosized metal 
particles might also act through an epigenetic mechanism, for instance by directly interacting 
with subcellular components of the mitotic machineries, giving rise to aneuploidy (Colognato 
et al., 2007). Investigations making use of in vitro, animal, and human studies have identified 
air pollutants (particulate matter, black carbon, and benzene) modifying epigenetic markers 
(Holloway et al., 2012). Most studies conducted to date have addressed DNA methylation 
(Szyf, 2011), whereas only a few investigations have studied histone modifications or 
microRNA expression (Cheng and Cho, 2012). Indeed, an increasing number of nanosized 
compounds has been found able to induce changes in the acetylation and methylation of 
histone tails as well as microRNA deregulated expression (Stoccoro et al., 2012). A 
comprehensive testing battery, however, should cover endpoints detectable at the gene, 
chromosome, and epigenetic levels and make use of a range of target cells (Lynch et al., 
2011). 
 
As a further important endpoint of concern, the impact of NM on the immune system should 
be a major component of NM safety assessment. Immune responses protect an organism 
from damage and disease. Interference with the normal course of a protective immune 
response can have detrimental effects. Thus, assessing the capacity of NM to alter the 
normal course of immune responses is of particular importance for hazard assessment 
(Boraschi et al., 2012). Interactions of NM with the immune system should be tested at the 
exposure site. Complex human primary models that include local immune cells can be used 
for this purpose, and several types of interactions should be assessed (Oostingh et al., 
2012):  
 
When interacting with immune cells, NM may induce a reaction, for instance inflammation in 
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the case of sentinel innate immune cells. During NM safety assessment, the type of 
inflammatory reaction requires further distinction: Inflammation can be a normal defense 
reaction. In this case, the inflammatory reaction is short-lived and beneficial in maintaining 
homeostasis of tissues, such as the barrier tissues, exposed to a stressful environment. 
Prolonged inflammation, however, is detrimental since it induces pathological tissue 
damage. The capacity of NM to induce protective vs. pathological inflammation should be 
evaluated in kinetic models using complex tissue-like human cell cultures. Profiling of the 
evolution of the response under normal conditions (successful elimination of the potentially 
dangerous agent and re-establishment of tissue homeostasis) will allow identification of 
possible immune-related derangements in the presence of NM (Oostingh et al., 2012). 
 
The majority of NM entering the body and not being immediately excreted ends up in the 
reticulo-endothelial system (RES) and are sequestered there. While RES cells have the task 
of destroying foreign materials, possible toxic effects of NM on these cells, in particular the 
mononuclear phagocytes of the different anatomical structures, is a major safety issue and 
must be carefully addressed (Boraschi et al., 2012), especially since elimination from the 
RES tissues may be very slow for some NM. 
Testing strategy to assess NM impact on the environment (i.e. ecotoxicity) 
 
A variety of methods and approaches for assessing the ecotoxicity and bioaccumulation of 
NM is already available, and further ones are under development. Underlining the 
fundamental difference between human health hazard and environmental hazard 
assessment, Figure 4 illustrates the main building blocks (i.e. different types of test methods 
and purposes of testing) of ecotoxicity testing strategies. These consist of laboratory tests, 
on the one hand (Figure 4; Building blocks 1a, 1b, and 1c; in blue, with Building block 1c in 
light blue, underlining that relevant test methods for this building block remain to be 
developed), and environmental simulation studies (Figure 2; Building block 2; in green). 
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Subsequently, Figures 5a and 5b present a proposal on how to integrate these building 
blocks into a tiered ecotoxicity testing strategy for NM.  
 
For assessing the impact of NM on the environment, both ecotoxicity and bioaccumulation 
will be determined making use of standardized laboratory test systems (Figure 4, Building 
block 1a), similar to the standardized procedures established for conventional chemicals 
(e.g. according to OECD Test Guidelines). In these test systems, standardized, and often 
artificial, test media are employed. Therefore, they only allow a general characterization of 
NM effects, and verification of the results from such tests taking into consideration 
environmentally relevant groups of organisms (Building block 1b) and realistic environmental 
exposure scenarios may be necessary (Building block 2) (von der Kammer et al., 2012). The 
complex interactions between NM, test media, and organisms may require amendment of 
existing test guidelines. Furthermore, the information obtained in standardized test systems 
is limited with regard to determining modes-of-action of the NM. This information (Figure 4, 
Building block 1c) may, however, be required for classifying NM, and it is likely to be a 
prerequisite for reduced, efficient testing aimed at a practical assessment of NM 
environmental hazard. Such suitable test systems beyond standardized testing, however, 
remain to be defined (Klaine et al., 2008; Handy et al., 2012a and 2012b).  
 
Likewise, further research is required to define which test systems are applicable for 
screening or confirmatory testing of the compliance of standardized laboratory tests using 
more specific tests with environmentally relevant organisms (Figure 4, Building block 1b). 
Depending on the potential environmental concerns identified in basic laboratory testing, 
further test species, endpoints, and food webs (interspecies transfer) might be studied in 
environmental simulation studies applying more realistic environmental exposure scenarios 
(Figure 4, Building block 2).  
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Since NM bioavailability is highly dependent on the chosen test conditions, care has to be 
taken when simulating environmentally relevant exposure. In this context, sedimentation and 
(hetero-)agglomeration of the NM or application of natural stabilizers, such as humic acids, 
and their variability under different environmental conditions have to be taken into account 
(Handy et al., 2012a and 2012b). Apart from providing data for environmental risk 
assessment, the results of environmental simulation studies performed under 
environmentally relevant exposure conditions can be used as basic information for 
environmental monitoring. Compartments, habitats, feeding types, or organisms identified as 
potentially endangered can trigger the need to collect specific environmental samples. Due 
to methodological limitations, however, such deliberations are currently speculative. 
 
Due to the diversity of NM in regard to type of material, shape, size, surface modification, 
crystalline structure, etc., for efficient ecotoxicological testing it is of special importance to be 
able to define groups of NM. Specific groups may comprise NM with comparable fate, 
behavior, and effects in the environment, as determined with the applied testing strategy 
(Stone et al., 2010). To obtain comprehensive information on the properties and effects of a 
given group, a sufficient number of materials belonging to it should be studied in detail. For 
further NM belonging to the same group, only recognized key parameters, such as the most 
sensitive endpoint making use of environmentally relevant organisms, remain to be 
addressed (Figure 4, building block 1b).  
 
Based upon these building blocks describing different purposes of ecotoxicity test methods, 
a tiered testing strategy to assess environmental hazards is proposed in Figures 5a and 5b. 
Testing begins with a selection of those tests considered necessary for the given NM (Figure 
5a; Tier 1). (In this context it remains a matter of further investigation to determine whether 
information from human toxicity tests are useful in supporting the selection of 
ecotoxicological endpoints). Depending on the main exposure path (i.e. water, sediment, 
soil), testing should be performed in aquatic, sediment, and/or terrestrial species. 
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Furthermore, it is advisable to include long-term testing alongside short-term testing from the 
beginning due to the persistent nature of many nanoparticle types.  
 
In the context of REACH, the choice of test systems and test organisms to be used for 
ecotoxicological testing of conventional chemicals depends on the production volume of the 
respective substance. In the case of NM, however, it seems more appropriate to base the 
testing scheme on expected concerns based upon routes of exposure, findings on 
physicochemical properties, and on fate studies, rather than production volume. Such an 
adaptation of the testing scheme seems permissible since the REACH guidance documents 
(ECHA, 2012) allow adapting the testing strategy in specific cases. Exposure route-driven 
selections of test systems are considered to be most appropriate, if exposure in soil and 
sediment is more likely than in pelagic systems. This may not always be the case, although 
one might intuitively assume that NM tend to agglomerate/aggregate and sink. Furthermore, 
higher exposure does not always equate with higher risks.  
 
All test results are compared with triggers (qualifiers). For conventional chemicals, such 
triggers are based on a comparison of the expected environmental concentration to the 
effect on mass basis corrected by assessment factors. It remains to be determined whether 
triggers comparable to those used for the testing of conventional chemicals can be applied 
for ecotoxicity testing of NM or whether modifications are required. For NM, expression of 
the environmental concentration on mass basis may be less suitable, and particle number 
concentration instead of mass concentration may be an appropriate alternative. To address 
these issues, further knowledge on NM exposure and fate are necessary. If such triggers are 
exceeded in Tier 1 test results, Tier 2 testing has to follow.  
 
In Tier 2 of the ecotoxicity testing strategy (Figure 5b), only the specific group of organisms 
or the environmental compartment has to be considered for which a potential unacceptable 
risk was identified in Tier 1. In Step 1 of Tier 2, further tests with further species, laboratory-
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scale simulation systems, and mode-of-action tests are performed as appropriate. In the 
second step of Tier 2, nanospecific aspects of particle exposure have to be taken into 
account: Since the testing conditions can affect surface functionalization, agglomeration 
behavior and bioavailability, it might be advisable to consider using natural stabilizers, such 
as humic acids, or to apply NM by simulating environmentally relevant pathways of entry. 
Analytical verification of the physico-chemical characteristics of the NM during testing may 
be necessary. Since however environmental conditions are highly variable, such simulations 
can only cover a limited number of different scenarios.  
 
Due to prevailing knowledge gaps in the area of environmental hazard assessment of NM, 
further research is needed to confirm and complete the proposed ecotoxicity testing strategy. 
Such research should address the following topics (Aschberger et al., 2011): 
 NM solubility, agglomeration, and heteroagglomeration processes in environmentally 
relevant media; 
 Selection of test organisms and endpoints for full NM testing (in standardized 
laboratory test systems): based upon concern, related e.g. to route of entry, rather 
than production volume? 
 NM modes-of-action: elaboration of suitable methods; 
 Criteria for classifying NM (particle characteristics vs. mode-of-action); 
 Confirmatory tests: Which organisms and endpoints should be considered? Are the 
test methods that proved most sensitive for the NM respective category sufficient? 
 Definition of triggers and qualifiers: Are the procedures applied for the testing of 
conventional chemicals suitable for NM? 
Grouping of NM for human health and environmental hazard assessment  
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Numerous NM are likely to find widespread applications in the near future, and a much 
greater number of modifications and uses of these NM is expected. It will be impossible to 
perform a full testing program on all NM with all modifications and in all use scenarios, 
notwithstanding that modifications or use/release scenarios may alter their biological effects 
(Som et al., 2012). Alternatively, it seems possible to assign certain biological effects to 
specific material properties (physical properties and chemical and sterical composition) and 
group NM based on these material characteristics (Zuin et al., 2012). Even though many NM 
have been shown to interact with cellular systems in vitro (inducing inflammation, ion 
release, catalysis of the formation of reactive species, or direct mechanical interaction), 
grouping of NM based on material characteristics has only been partly successful to date: So 
far no single material property – be it surface, volume or generation of reactive oxygen 
species – perfectly correlates with the observed biological effects for various types of NM. 
Therefore grouping of NM should be a high research priority for the next years.  
 
As illustrated in Figure 6, alternative or complementary groupings of NM may be based on:  
 Similar biopersistence and biokinetic characteristics. Fate and kinetics may also give 
a measure for grouping/summing nanomaterials, e.g. if the distribution and mode-of-
action are the same, but the bioavailability is different (due to e.g. differences in size). 
Identical distribution patterns in tissue of environmental compartments might also be 
a criterion for grouping different NM. If a nanomaterial shows a deviating distribution 
pattern, this may result in different effects and/or different target species for 
environmental exposure. 
 Similar or common biological effects, including early effects and NM-cell structure-
interactions. The latter approach can be served by cellular assays as well as short-
term in vivo tests.  
 
These specifications reveal that a given NM could belong to more than one group. 
Furthermore, grouping based on early biological effects is tightly linked to the adverse 
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outcome pathways concept (Ankley et al., 2010; OECD, 2012) and the so-called Tox21c 
Initiative in the USA (Firestone et al., 2010). Hence, grouping of NM by concern is 
considered a potential route. 
 
Grouping of substances should form an integral part of any NM testing strategy. In the 
course of NM toxicity and ecotoxicity testing, it seems an effective and efficient approach to 
combine exposure, fate, biokinetics, and hazard data for risk assessment and grouping 
purposes. This document envisions a guidance regarding the integration of material 
properties, exposure, biokinetics, and hazard data, which therefore should be a high priority 
for future research on the safety assessment of nanomaterials. 
Recommendations for the human health and environmental hazard 
assessment of NM 
 
A. Testing Strategies 
1. Find an approach to deal with changing characteristics, and thus hazard, of NM 
during their life cycle 
2. Integrate exposure, material properties, biopersistence, biokinetics (ADME/ADCE) as 
well as primary effect and apical effect testing into a concern-driven testing strategy 
that can be applied to an individual NM but also includes guidance for grouping of 
NM. Use all available information to identify relevant concerns and to choose the 
right studies to be performed. Fill in the criteria for the decision-making process of the 
concern-driven tiered testing strategy. 
3. Use grouping as an integral part of the testing strategy 
4. Define adverse outcome pathways for different NM 
5. Use data obtained in A.2, A.3, and A.4 to fill in criteria for grouping of NM  
6. Define triggers for Tier 2 and 3 for human health risk assessment 
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7. Define trigger values for environmental risk assessment 
o Provide guidance on the extent of ecotoxicity testing (terrestrial vs. aquatic 
tests) 
o Provide guidance on the consideration of accumulation (which criteria trigger 
accumulation testing in individual organisms or in the food web) 
o Provide guidance on the selection of ecotoxicological tests for compliance 
testing 
 
B. Testing Methods 
1. Designate potential testing methods applied to NM to be of use for each concern 
2. Define a list of NM as performance standards for testing methods  
(ideally covering different toxic effects and including positive and negative controls) 
3. Update and amend existing testing methods for specific needs of NM testing  
o Provide guidance on NM dispersion and in situ characterization in the test 
system 
o Provide guidance on methods to study biokinetics (ADME/ADCE) and 
biopersistence, and on application of these data 
o Provide guidance on development and application of testing methods as part 
of a testing strategy rather than as stand-alone tests 
o Provide guidance for the simulation of increased environmentally relevant 
exposure; e.g. application of natural stabilizers 
4. Update and amend existing testing methods in general (for NM and chemicals alike) 
o Bronchoalveolar lavage in inhalation studies 
o Extended histopathology (e.g. lung) 
o Aquatic and terrestrial ecotoxicity tests 
5. Establish general concepts for NM (and other particles) effects 
o Carcinogenicity 
o Cardiovascular effects 
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o Epigenetic effects 
o Immunological effects 
o Reproductive toxicity, developmental toxicity 
6. Establish concepts for environmental monitoring to verify the effects detected in 
laboratory tests or simulation tests 
 
C. Grouping of NM 
 
1. For grouping to be used as an integral part of the testing strategy, define and validate 
scientifically sound grouping criteria based on available data and material properties 
(metrology), biopersistence, fate, ADME/ADCE as well as primary and apical effects 
2. Use QSAR, if applicable 
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Figure captions 
 
Figure 1:  
Physicochemical characterization, dispersion, and in situ characterization of NM for toxicity testing 
Footnote to Figure 1: 
NanoCare SOPs available at:  http://www.nanopartikel.info/cms/lang/de/Projekte/NanoCare/NanoCare-
Publikationen 
NanoGem SOPs available at: http://www.nanogem.de/cms/nanogem/front_content.php?idcat=159&lang=10  
 
Figure 2:  
Targeted integrated approach to NM toxicity testing and assessment addressing the specific concerns for an 
individual NM 
 
Figure 3:  
Identification of potential health concerns of an individual NM based upon its physicochemical properties and 
relevant exposure scenarios (numberings of Tiers relate to Figure 2) 
 
Figure 4:  
Building blocks for integrated approaches to ecotoxicity testing and assessment, i.e. different types of test 
methods and purposes for ecotoxicity testing 
 
Figure 5a: 
Proposal for Tier 1 of an integrated approach to ecotoxicity testing and assessment (numberings 1a and 1c refer 
to the respective building blocks presented in Figure 4) 
 
Figure 5b:  
Proposal for Tier 2 of an integrated approach to ecotoxicity testing and assessment (numberings 1b, 1c, and 2 
refer to the respective building blocks presented in Figure 4)   
 
Figure 6:  
Illustration of grouping of NM based on material properties and/or biological effects. This schematic example 
shows three groups of NM and also NM not assignable to any group 
